Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
With an eye on a swelling Chinese market, Roche unveiled Phase III data showing a combination of Tecentriq, its immunotherapy, and Avastin could help patients with the most common form of liver cancer live longer than under the standard treatment, Bayer’s Nexavar.
In a trial of 501 unresectable hepatocellular carcinoma patients, Roche’s cocktail reduced the risk of death by 42% and the risk of cancer progression by 41% as compared to Nexavar. Enough Tecentriq patients have lived long enough that Roche couldn’t yet determine the median OS but those on Nexavar passed away after a median of 10.4 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.